New Ulcerative Colitis Medication from Pfizer on the Horizon – Tofacitinib
Unlike biologics, which target extracellular molecules such as pro-inflammatory cytokines, tofacitinib targets the intracellular signaling pathways that operate as hubs in the inflammatory cytokine network. It’s goal is to reduce the inflammatory response much like several other medications that are currently FDA approved.